PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10216478-1 1999 BACKGROUND: We investigated the feasibility and efficacy of high-dose chemotherapy consisting of ifosfamide, carboplatin and etoposide (HD-ICE) facilitated by autologous peripheral blood progenitor cell transplantation (ABPCT) for the treatment of small-cell lung cancer (SCLC). Etoposide 125-134 carboxylesterase 2 Homo sapiens 139-142 18573848-5 2008 Chemotherapy consisted of ifosfamide, cisplatin and etoposide (ICE chemotherapy). Etoposide 52-61 carboxylesterase 2 Homo sapiens 63-66 16702184-1 2006 The age-adjusted International Prognostic Index assessed before salvage therapy with ICE (ifosfamide, carboplatin, etoposide) predicts outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). Etoposide 115-124 carboxylesterase 2 Homo sapiens 85-88 15287915-0 2004 ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. Etoposide 30-39 carboxylesterase 2 Homo sapiens 0-3 15287915-1 2004 OBJECTIVE: To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate. Etoposide 53-62 carboxylesterase 2 Homo sapiens 23-26 12736226-0 2003 Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin"s lymphoma. Etoposide 62-71 carboxylesterase 2 Homo sapiens 75-78 11589488-0 2001 Three conventional-drug combination (ifosfamide, carboplatin, etoposide--ICE regimen) in advanced non-small cell lung cancer (NSCLC). Etoposide 62-71 carboxylesterase 2 Homo sapiens 73-76 10642996-5 2000 After the operation, we treated him with additional radiation and chemotherapy using ifosfamide, cisplatin, and etoposide (namely ICE therapy). Etoposide 112-121 carboxylesterase 2 Homo sapiens 130-133 12215019-5 2002 Another risk factor of infection was the HD-ICE regimen (ifosfamide, carboplatin, etoposide) given to patients with solid tumors (OR, 8.00; 95% confidence interval, 1.61-39.7). Etoposide 82-91 carboxylesterase 2 Homo sapiens 44-47 12042984-29 2002 Therapy with a similar regimen, combining ifosfamide, carboplatin, and etoposide in standard doses (ICE) has also been described. Etoposide 71-80 carboxylesterase 2 Homo sapiens 100-103 12803126-1 2002 BACKGROUND: Big ICE chemotherapy (consisting of Idarubicin, high dose Cytosine arabinoside and Etoposide), has proven its efficacy in the treatment of patients with relapse/refractory acute myeloblastic leukemia. Etoposide 95-104 carboxylesterase 2 Homo sapiens 16-19 10577849-1 1999 PURPOSE: To evaluate a chemotherapy regimen that consisted of ifosfamide administered as an infusion with bolus carboplatin, and etoposide (ICE) supported by granulocyte colony-stimulating factor (G-CSF) for cytoreduction and stem-cell mobilization in transplant-eligible patients with primary refractory or relapsed non-Hodgkin"s lymphoma (NHL). Etoposide 129-138 carboxylesterase 2 Homo sapiens 140-143 9876059-0 1998 Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC). Etoposide 45-54 carboxylesterase 2 Homo sapiens 56-59 9885442-0 1998 Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin"s lymphoma. Etoposide 53-62 carboxylesterase 2 Homo sapiens 73-76 9885442-1 1998 The combination of ifosfamide, carboplatin and etoposide (modified ICE), was evaluated for its toxicity and activity in relapsed or refractory aggressive non-Hodgkin"s lymphoma. Etoposide 47-56 carboxylesterase 2 Homo sapiens 67-70 9876059-1 1998 We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC). Etoposide 65-74 carboxylesterase 2 Homo sapiens 76-79 9329558-3 1997 These trials were extended to 2 sequential phase II investigations of WBH plus ifosfamide, carboplatin and etoposide (ICE) for refractory sarcoma patients. Etoposide 107-116 carboxylesterase 2 Homo sapiens 118-121 33761503-11 2021 He received 3 cycles of chemotherapy with ICE regimen (ifosfamide, carboplatin, and etoposide). Etoposide 84-93 carboxylesterase 2 Homo sapiens 42-45 8899175-0 1996 The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic disease. Etoposide 42-51 carboxylesterase 2 Homo sapiens 4-7 7602350-1 1995 PURPOSE: A phase II study of ifosfamide, carboplatin, and prolonged oral administration of etoposide (ICE) in patients with untreated extensive-disease (ED) small-cell lung cancer (SCLC) was conducted to assess toxicities, response, and median survival. Etoposide 91-100 carboxylesterase 2 Homo sapiens 102-105 7610396-1 1995 The combination of ifosfamide (with mesna uroprotection), carboplatin, and etoposide (ICE) has demonstrated activity in a variety of cancers. Etoposide 75-84 carboxylesterase 2 Homo sapiens 86-89 7610397-3 1995 Combining ifosfamide, carboplatin, and etoposide, among the most active single agents against SCLC, into the ICE regimen was a logical move that has resulted in improved response and survival rates. Etoposide 39-48 carboxylesterase 2 Homo sapiens 109-112 7610398-1 1995 We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer. Etoposide 86-95 carboxylesterase 2 Homo sapiens 125-128 7758997-4 1995 Experience gathered in recent years shows that idarubicin, cytosine arabinoside, and etoposide together might contribute to the modeling of an improved remission induction regimen: ICE. Etoposide 85-94 carboxylesterase 2 Homo sapiens 181-184 8677446-6 1996 Maximum tolerated doses of the ICE regimen in these trials are 16 to 20.1 g/m2 ifosfamide, 1.8 g/m2 carboplatin, and 1.2 to 3.0 g/m2 etoposide. Etoposide 133-142 carboxylesterase 2 Homo sapiens 31-34 8677454-2 1996 The ICE combination (ifosfamide/carboplatin [or cisplatin]/etoposide) has been studied in breast cancer, small cell and non-small cell lung cancer, testicular cancer, lymphoma, and other malignancies with promising results. Etoposide 59-68 carboxylesterase 2 Homo sapiens 4-7 32006654-5 2020 Single cell gel electrophoresis assay and H2DCFDA analysis revealed that the expression of ALDH3A1 protected HCE-2 cells from H2O2-, tert-butyl peroxide- and etoposide-induced oxidative and genotoxic effects. Etoposide 158-167 carboxylesterase 2 Homo sapiens 109-114 34329577-2 2021 The aim of this study is to establish the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma. Etoposide 139-148 carboxylesterase 2 Homo sapiens 153-156 32945942-3 2020 The ICE (ifosfamide, cyclophosphamide, and etoposide) regimen is often used as salvage therapy for r/r DLBCL. Etoposide 43-52 carboxylesterase 2 Homo sapiens 4-7 33121007-1 2020 CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. Etoposide 66-75 carboxylesterase 2 Homo sapiens 80-98 33121007-1 2020 CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. Etoposide 66-75 carboxylesterase 2 Homo sapiens 100-104 26221234-6 2015 He was subsequently treated with five courses of the salvage chemotherapy regimen ICE (ifosfamide, carboplatin and etoposide) and achieved PR again. Etoposide 115-124 carboxylesterase 2 Homo sapiens 82-85 31122751-9 2019 Despite second-line chemotherapy with R-ICE (rituximab-ifosfamide, carboplatin and etoposide), the patient died. Etoposide 83-92 carboxylesterase 2 Homo sapiens 40-43 26374553-2 2015 The aim of this study was to assess the efficacy and safety of ifosfamide in combination with carboplatin and etoposide (ICE) in previously untreated patients with SCLC. Etoposide 110-119 carboxylesterase 2 Homo sapiens 121-124 28208865-4 2016 The patient was administered 3-cycles of neo-adjuvant chemotherapy with ifosphamide, carboplatin and etoposide (ICE-chemotherapy) and subsequently 3 more cycles of chemotherapy post surgery, followed by radiation. Etoposide 101-110 carboxylesterase 2 Homo sapiens 112-115 26365969-0 2015 Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas. Etoposide 42-51 carboxylesterase 2 Homo sapiens 53-56 26365969-2 2015 This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. Etoposide 85-94 carboxylesterase 2 Homo sapiens 96-99 24944079-1 2014 ICE/R-ICE (ifosfamide, carboplatin, and etoposide without or with rituximab) chemotherapy followed by autologous stem cell transplantation is an established regimen in refractory/relapsed lymphoma. Etoposide 40-49 carboxylesterase 2 Homo sapiens 0-3 24944079-1 2014 ICE/R-ICE (ifosfamide, carboplatin, and etoposide without or with rituximab) chemotherapy followed by autologous stem cell transplantation is an established regimen in refractory/relapsed lymphoma. Etoposide 40-49 carboxylesterase 2 Homo sapiens 6-9 22099936-4 2011 The aim of this study is to evaluate the response rate of salvage chemotherapy by the ICE (Ifosfamide, Carboplatin, and Etoposide) regimen when administered to previously treated primary refractory or progressive high risk neuroblastoma patients. Etoposide 120-129 carboxylesterase 2 Homo sapiens 86-89 19701081-2 2010 Treatment with a comprehensive program using second-line chemotherapy with ICE (ifosfamide, carboplatin, etoposide) before HDT/ASCT identified a clinical prognostic model, but prognostic biologic markers in relapsed/refractory HL remain unclear. Etoposide 105-114 carboxylesterase 2 Homo sapiens 75-78 22525550-5 2012 After induction chemotherapy with ICE (Ifosfamide, Carboplatin, Etoposide), she developed neutropenia and high fever without apparent infective foci. Etoposide 64-73 carboxylesterase 2 Homo sapiens 34-37